Payment overview · 2025
General Payments
$670.86
7 reported records · 5 companies
Healthcare provider profile · identity verified
Kangxia Gu, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLUSHING, NY · NPI 1750631446
Verified facts
What the public records show
CMS Open Payments records show Kangxia Gu, MD received $670.86 in general payments during 2025 across 7 reported records.
PolyNovo North America LLC accounted for 55.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Vemlidy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PolyNovo North America LLC | Unresolved — no canonical attribution shown | $371.35 | 55.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $139.19 | 20.8% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $130.00 | 19.4% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $16.01 | 2.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.31 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $670.86 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NOVOSORB BTM Normalized: novosorb btm |
Device | PolyNovo North America LLC | $371.35 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $139.19 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $130.00 | 1 | 2025 |
Source payment records
|
|||||
| Repatha Normalized: repatha |
Biological | Amgen Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 912 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 858 | 140 |
| Losartan Potassium | Losartan Potassium | 514 | 88 |
| Vascepa | Icosapent Ethyl | 459 | 71 |
| Simvastatin | Simvastatin | 291 | 44 |
| Metformin Hcl | Metformin Hcl | 274 | 43 |
| Omeprazole | Omeprazole | 219 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 199 | 33 |
| Ammonium Lactate | Ammonium Lactate | 197 | 30 |
| Metformin Hcl Er | Metformin Hcl | 162 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 135 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 32 |
| Atenolol | Atenolol | 118 | 15 |
| Finasteride | Finasteride | 114 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 110 | 37 |
| Lisinopril | Lisinopril | 106 | 19 |
| Januvia | Sitagliptin Phosphate | 105 | 17 |
| Trazodone Hcl | Trazodone Hcl | 105 | 25 |
| Alendronate Sodium | Alendronate Sodium | 98 | 20 |
| Raloxifene Hcl | Raloxifene Hcl | 92 | 16 |
| Diclofenac Epolamine | Diclofenac Epolamine | 90 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 81 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 12 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 61 | 61 |
| Glimepiride | Glimepiride | 61 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 60 | 21 |
| Glipizide Er | Glipizide | 55 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 52 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | suppressed |
| Acarbose | Acarbose | 46 | suppressed |
| Jardiance | Empagliflozin | 46 | suppressed |
| Nateglinide | Nateglinide | 46 | suppressed |
| Gabapentin | Gabapentin | 45 | 13 |
| Montelukast Sodium | Montelukast Sodium | 43 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 37 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Eliquis | Apixaban | 29 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Allopurinol | Allopurinol | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 14 |
| Valsartan | Valsartan | 19 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Azithromycin | Azithromycin | 15 | 14 |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Propylthiouracil | Propylthiouracil | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Alogliptin-Metformin | Alogliptin Benz/Metformin Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Entecavir | Entecavir | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 11 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $670.86 · 7 records | PolyNovo North America LLC | JARDIANCE, LYBALVI, NOVOSORB BTM, Repatha | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error